Skip to main content
. 2022 May 17;5(9):e202101235. doi: 10.26508/lsa.202101235

Figure S2. DUSP4 knockdown shows an impaired cell growth in melanoma cells.

Figure S2.

(A) SKMEL28 and COLO829 melanoma cells were transfected with siRNAs against DUSP4, DUSP6, DUSP10, or with a nontargeting control. The panels show representative images of the cell growth after 5 d of transfection. (A, B) Cells were treated as in (A). mRNA levels of DUSP4, DUSP6, and DUSP10 were determined by RT–qPCR and were referred to the expression level of siNT cells. Data are normalized to GAPDH and represent mean of three independent experiments. (A, C) Cells were transfected with siRNAs against DUSP4 or with a nontargeting control as in (A). The panels show representative images of the cell growth after 5 d of transfection. (D) Lysates from siNT and siDUSP4 transfected melanoma cells were analyzed by immunoblotting at 48-h post-transfection. (E) Dox-inducible shDUSP4 (shDUSP4-1 and shDUSP4-2) and nontargeting control (shNT) SKMEL28 cell clones were treated with or without doxycycline (0.5 μg/ml). After 48 h, cell lysates were analyzed by Western Blot. (F) Cell growth from Dox-inducible shDUSP4 (shDUSP4-1 and shDUSP4-2) and nontargeting control (shNT) SKMEL28 cell clones was analyzed by Incucyte over time.